BioVector? 患者源性腫瘤類器官株技術(shù)說明書 BioVector? Patient-Derived Tumor Organoids (PDOs)

第一部分：中文說明

一、 產(chǎn)品基本信息與詳細特征描述

• 產(chǎn)品名稱：BioVector? 患者源性腫瘤類器官株

• 產(chǎn)品編碼：BioVector? PDO-Series（根據(jù)瘤種及患者編號具體指定，如 PDO-CRC-012XL 結(jié)直腸癌、PDO-PDAC-045 胰腺癌）

• 物種來源：人類 (Homo sapiens)

• 組織來源：經(jīng)患者臨床手術(shù)切除標(biāo)本或穿刺活檢組織（均簽署無菌知情同意書并獲本中心及醫(yī)院 IRB 倫理批準(zhǔn)）

• 細胞屬性：三維空間結(jié)構(gòu)多細胞復(fù)合體 (3D Multicellular Complex) / 懸浮于細胞外基質(zhì)基托中生長

• 生物安全級別：2級 (BSL-2) —— 注：本品來源于人類原發(fā)腫瘤組織，具有潛在的人類病原體風(fēng)險，所有操作必須在二級生物安全柜中進行。

• 詳細特征描述：BioVector? 患者源性腫瘤類器官 (Patient-Derived Tumor Organoids, PDOs) 是當(dāng)前腫瘤精準(zhǔn)醫(yī)學(xué)、靶向藥/免疫治療耐藥機制研究以及轉(zhuǎn)化醫(yī)學(xué)領(lǐng)域最具革命性的體外單細胞與多細胞復(fù)合疾病模型。與經(jīng)歷數(shù)十年體外傳代、發(fā)生嚴重遺傳漂移的傳統(tǒng)二維（2D）腫瘤細胞株不同，PDO 在三維自組裝培養(yǎng)體系中高度保留了原發(fā)腫瘤的組織學(xué)異質(zhì)性、細胞空間排列、三維基因組學(xué)拓撲結(jié)構(gòu)、表觀遺傳學(xué)特征以及染色體非整倍體等復(fù)雜的突變譜（如 KRAS, TP53, BRCA1/2 等驅(qū)動突變）。在倒置顯微鏡下，不同瘤種的 PDO 表現(xiàn)為獨特的出芽狀、中空囊泡狀或致密球狀的多細胞聚集體。由于其極高地模擬了患者體內(nèi)的真實腫瘤表型與臨床藥物響應(yīng)，在《Nature》、《Cell》以及《The Lancet Oncology》等頂級頂刊的最新研究中，PDO 已被公認為高通量藥物協(xié)同毒性篩選（Pharmacogenomics）與個性化精準(zhǔn)醫(yī)療的“金標(biāo)準(zhǔn)”臨床前模型。

二、 細胞培養(yǎng)環(huán)境、底盤基質(zhì)與專用培養(yǎng)基配方

• 核心基質(zhì)依托（關(guān)鍵添加）：PDO 無法直接貼壁于普通塑料表面，必須完全包裹/懸浮于富含層粘連蛋白和膠原蛋白的細胞外基質(zhì)（如 BioVector? Matrigel / 減生長因子基質(zhì)膠）中，形成直徑約 30–50 $\mu\text{L}$ 的三維“果凍穹隆（Domes）”，上方覆蓋溫?zé)岬膶Ｓ猛耆囵B(yǎng)基。

• 標(biāo)準(zhǔn)完全培養(yǎng)基配方（以結(jié)直腸癌 PDO 為例）：

  • 基礎(chǔ)培養(yǎng)基：Advanced DMEM/F12 營養(yǎng)肉湯。

  • 微環(huán)境核心因子（特定激活/抑制劑組）：

    • Wnt通路激活劑：Wnt-3A 調(diào)節(jié)培養(yǎng)物（或分級釋放劑 50%）。

    • R-spondin 1 (1 $\mu\text{g/mL}$) 與 Noggin (100 ng/mL) —— 維持干細胞特性的“三因子”核心。

    • EGF (表皮生長因子)：50 ng/mL。

    • 小分子抑制劑（防失巢凋亡）：Y-27632 (ROCK抑制劑)，終濃度 10 $\mu\text{M}$（僅在復(fù)蘇后或傳代消化后的前 48 小時添加，隨后更換為不含 Y-27632 的培養(yǎng)基）。

    • 其他輔助添加：B27 添加劑 (1×)、N-乙酰半胱氨酸 (1.25 mM)、Nicotinamide (10 mM)、SB202190 (p38抑制劑，10 $\mu\text{M}$)、A83-01 (TGF-$\beta$受體抑制劑，500 nM)。

• 物理培養(yǎng)參數(shù)：

  • 培養(yǎng)溫度與氣體：37°C 恒溫、5% 二氧化碳 ($CO_2$)、飽和空氣濕度培養(yǎng)箱。

三、 類器官傳代、復(fù)蘇與高通量藥物篩選標(biāo)準(zhǔn)操作步驟

1. 常規(guī)三維類器官傳代操作 (周期 7–10 天，根據(jù)生長速度而定)：

   • 當(dāng)類器官體積過大（中心開始出現(xiàn)暗色壞死核心）或基質(zhì)膠內(nèi)部過密時，吸除上清培養(yǎng)基。

   • 每孔加入 1–2 mL 冰稀釋的無菌 PBS（不含鈣鎂離子），用移液槍反復(fù)吹打基質(zhì)膠拱頂（Domes），使基質(zhì)膠在低溫下完全融化。

   • 將懸液轉(zhuǎn)移至 15 mL 離心管中，于 4°C 下、每分鐘 300-400 轉(zhuǎn)（低速離心）離心 3 分鐘，棄上清以去除融化的基質(zhì)膠。

   • 加入 1-2 mL 預(yù)熱的 BioVector? Organoid Dissociation Enzyme（類器官專用機械/酶學(xué)消化液，如 TrypLE Express），置于 37°C 孵育 5–8 分鐘。其間可溫和吹打，顯微鏡下觀察到類器官被打碎成 10-50 個細胞的小細胞團簇（切勿消化成單個細胞，否則會導(dǎo)致大面積凋亡）。

   • 加入含血清的基礎(chǔ)培養(yǎng)基終止消化，300g 離心 3 分鐘。用未融化的冰育基質(zhì)膠重懸細胞團，以 40 $\mu\text{L}$/滴的體積接種于預(yù)熱的 24 孔板底，放入培養(yǎng)箱 15 分鐘待其固化成型，隨后覆蓋溫?zé)岬耐耆囵B(yǎng)基（前 48 小時含 Y-27632）。

2. 深凍保藏類器官復(fù)蘇：

   • 從液氮中取出類器官凍存管，在 37°C 水浴中快速搖動融化（1-2 分鐘內(nèi)）。

   • 將類器官懸液移至含 5 mL 冰冷 Advanced DMEM/F12 的離心管中，300g 離心 3 分鐘以去除含高濃度 DMSO 的凍存液。

   • 棄上清，用未融化的冰育基質(zhì)膠重懸細胞團簇，接種成 Dome，固化后加入富含 10 $\mu\text{M}$ Y-27632 的完全培養(yǎng)基進行恢復(fù)培養(yǎng)。

3. 高通量藥物敏感性分析 (Drug Screening Assay)：

   • 收集消化成微小細胞團的 PDO，將其以精確的細胞密度混合于稀釋的低濃度基質(zhì)膠（最終基質(zhì)膠含量為 5%-10%）中，利用排槍接種至不透明白底 384 孔板或 96 孔板（每孔約 1000–2000 個細胞）。

   • 培養(yǎng) 3-4 天使類器官初步成型，加入不同濃度梯度的靶向藥、化療藥或免疫偶聯(lián)物（ADCs）。

   • 持續(xù)孵育 72 小時至 120 小時。通過 BioVector? CellTiter-Glo? 3D 細胞活性測定試劑盒（基于ATP發(fā)光法）檢測相對發(fā)光值，精準(zhǔn)繪制藥物劑量反應(yīng)曲線并計算 $IC_{50}$ 值。

四、 類器官長期保藏與凍存技術(shù)

• 標(biāo)準(zhǔn)凍存液配方：推薦使用高效的無血清類器官專用凍存液，或配制：80% 完全培養(yǎng)基 + 10% 優(yōu)質(zhì)胎牛血清 (FBS) + 10% 二甲基亞砜 (DMSO) + 10 $\mu\text{M}$ Y-27632。

• 冷凍保存程序：傳代過程中，在用酶消化成小細胞團簇（而非單細胞）后離心收集。用預(yù)冷的類器官凍存液輕輕重懸，迅速分裝入無菌凍存管。移入標(biāo)準(zhǔn)程序降溫盒（如 Mr. Frosty，每分鐘降溫 1°C）置于 -80°C 冰箱過夜，次日必須立即轉(zhuǎn)移至液氮罐（-196°C）的氣相中進行長期保藏，以確保復(fù)蘇后的高成活率與形態(tài)恢復(fù)能力。

五、 質(zhì)量控制標(biāo)準(zhǔn)與前沿科研應(yīng)用指南

• 質(zhì)量控制標(biāo)準(zhǔn)：BioVector? 提供的各批次 PDO 株均經(jīng)過極其嚴格的臨床關(guān)聯(lián)質(zhì)量控制。經(jīng) PCR 篩查確認 100% 無支原體、細菌、真菌及常見人類傳染病病原體（HIV, HBV, HCV 等）污染；通過 STR（短串聯(lián)重復(fù)序列）指紋圖譜鑒定，確保其與患者原發(fā)腫瘤組織圖譜 100% 匹配；經(jīng)高通量測序（WES/RNA-seq）證實穩(wěn)定保留了原發(fā)灶的核心驅(qū)動基因突變表型；3D 空間成膜和多細胞出芽能力保持多世代高度穩(wěn)定。

• 核心實驗應(yīng)用方向：

  • 臨床精準(zhǔn)抗癌藥物伴隨診斷：作為患者個體的“替身”，在臨床用藥前快速篩查不同藥物組合的敏感性，預(yù)測臨床療效。

  • 腫瘤耐藥與進化分子機制：利用 CRISPR-Cas9 質(zhì)粒系統(tǒng)直接在 PDO 中進行基因敲除，解析靶向藥物（如 EGFR 抑制劑或 KRAS-G12C 抑制劑）在長期暴露下的獲得性耐藥機制。

  • 腫瘤微環(huán)境（TME）重構(gòu)共培養(yǎng)：將 PDO 與患者自身的自體浸潤淋巴細胞（TILs）、巨噬細胞或成纖維細胞（CAFs）進行三維共培養(yǎng)，用于動態(tài)評估全新設(shè)計的 CAR-T 細胞或雙特異性抗體在空間屏障下的浸潤與殺傷效能。

PART 2: ENGLISH SECTION

I. General Information and Detailed Product Characterization

• Product Name: BioVector? Patient-Derived Tumor Organoids (PDOs) Standard Datasheet

• Product Catalog Code: BioVector? PDO-Series (Designated according to specific cancer types and donor identification, e.g., PDO-CRC-012XL for Colorectal Cancer, PDO-PDAC-045 for Pancreatic Ductal Adenocarcinoma)

• Species Origin: Human (Homo sapiens)

• Tissue Source: Isolated from freshly resected tumor specimens or core needle biopsies (Procured with strict aseptic donor informed consent under institutional IRB approval).

• Cell Category: Three-Dimensional Multicellular Complex / Suspended within extracellular matrix anchors.

• Biosafety Level: BSL-2 —— CRITICAL NOTE: This product comprises primary human-derived oncological biomaterials carrying potential human pathogen vectors. All experimental workflows must be strictly restricted to certified Level II Biosafety Cabinets (BSCs).

• Detailed Description: BioVector? Patient-Derived Tumor Organoids (PDOs) represent the most revolutionary avant-garde in vitro disease models currently deployed across clinical oncology, high-throughput drug resistance profiling, and translational medicine networks. Distinct from immortalized two-dimensional (2D) tumor lines that have undergone severe genetic drift and clonal homogenization over decades of plastic passaging, PDOs propagated within a 3D self-assembling niche robustly maintain the histopathological heterogeneity, spatial cellular cytoarchitecture, three-dimensional genomic topography, epigenetic landscape, and complex chromosomal aneuploidies of the original patient tumor (e.g., driver mutations in KRAS, TP53, BRCA1/2). Under inverted microscopic evaluation, PDOs present unique morphotypes ranging from hollow cystic spheres and highly branched budding structures to dense solid aggregates, depending on the tissue of origin. Because they mirror the authentic in vivo tumor architecture and patient-specific therapeutic responses, PDOs are universally acknowledged as the gold-standard preclinical testing platform for high-throughput combinatorial pharmacogenomics in high-impact journals like Nature, Cell, and The Lancet Oncology.

II. Cultivation Environments, Extracellular Matrices, and Medium Formulations

• Core Matrix Anchoring (Critical Component): PDOs cannot attach directly to conventional plastic surfaces. They must be fully embedded and suspended inside an extracellular matrix support (such as BioVector? Matrigel / Growth Factor Reduced Basement Membrane Matrix) to form 30–50 $\mu\text{L}$ three-dimensional "Domes," which are then overlayed with warm, tissue-specific complete organoid medium.

• Standardized Colorectal Cancer PDO Complete Medium Formulation (Example):

  • Basal Medium: Advanced DMEM/F12 Nutrient Broth.

  • Niche Core Essential Factors:

    • Wnt Signaling Potentiator: Wnt-3A conditioned medium (or defined recombinant equivalents at 50% v/v).

    • R-spondin 1 (1 $\mu\text{g/mL}$) & Noggin (100 ng/mL) —— The indispensable core triad to maintain stemness characteristics.

    • EGF (Epidermal Growth Factor): 50 ng/mL.

    • Anoikis Prevention Cocktail: Y-27632 (ROCK Inhibitor) at a final concentration of 10 $\mu\text{M}$ (Mandatory ONLY during the initial 48 hours post-thawing or post-dissociation; must be omitted during regular media replenishments).

    • Auxiliary Supplements: B27 Supplement (1×), N-Acetylcysteine (1.25 mM), Nicotinamide (10 mM), SB202190 (p38 MAPK Inhibitor, 10 $\mu\text{M}$), A83-01 (TGF-$\beta$ Receptor Inhibitor, 500 nM).

• Physical Processing Criteria:

  • Incubation Environment: Constantly maintained at 37°C under an atmosphere of 5% Carbon Dioxide ($CO_2$) and saturated relative humidity.

III. Subculturing, Cryovial Thawing, and High-Throughput Screening Protocols

1. Routine 3D Organoid Passaging Workflow (7–10 Day Cycle, Kinesthetically Density-Driven):

   • Initiate subculturing when organoid diameters become excessive (often manifesting dark, necrotic hypoxic cores) or when the matrix domes become overcrowded.

   • Aspirate the overlaying spent medium and dispense 1–2 mL of ice-cold sterile, calcium- and magnesium-free PBS per well. Repeatedly pipette the matrix domes to break them apart, allowing the Matrigel to fully liquefy under low-temperature conditions.

   • Transfer the slurry into a 15 mL conical tube and centrifuge at a gentle 300g (approximately 300–400 RPM depending on rotor radius) at 4°C for 3 minutes. Decant the supernatant containing the dissolved matrix remnants.

   • Dispense 1–2 mL of pre-warmed BioVector? Organoid Dissociation Enzyme (e.g., TrypLE Express) and incubate at 37°C for 5–8 minutes. Periodically pipette the solution gently. Monitor under an inverted microscope until the organoids are disrupted into small multicellular clusters containing roughly 10–50 cells (CRITICAL: Do not dissociate into single cells, as this triggers catastrophic anoikis-driven apoptosis).

   • Neutralize the enzymatic activity by adding serum-containing basal medium and spin at 300g for 3 minutes. Resuspend the organoid pellet in chilled, unpolymerized Matrigel. Dispense 40 $\mu\text{L}$ droplets onto the pre-warmed surface of a 24-well plate. Invert and place the plate inside the incubator for 15 minutes to allow the matrix to fully polymerize into stable domes before overlaying with complete organoid medium (supplemented with Y-27632 for the first 48 hours).

2. Cryopreserved Aliquot Thawing:

   • Retrieve a PDO cryovial from the liquid nitrogen tank and instantly submerge it into a 37°C water bath, swirling continuously for 1–2 minutes until the icy mass liquefies.

   • Transfer the organoid solution into a sterile tube containing 5 mL of ice-cold Advanced DMEM/F12 and spin at 300g for 3 minutes to cleanly eliminate the toxic DMSO cryoprotectants.

   • Discard the supernatant, blend the cell pellet evenly into chilled Matrigel, and seed the domes. Following polymerization, cover with complete medium enriched with 10 $\mu\text{M}$ Y-27632 to maximize post-thaw recovery rates.

3. High-Throughput Drug Sensitivity Bioassay:

   • Harvest log-phase PDOs and gently dissociate them into micro-clusters. Blend them thoroughly into a diluted matrix solution (targeting a final concentration of 5%–10% Matrigel) to adjust the cell density to approximately 1000–2000 cells per well. Dispense the mixture into opaque, white-walled 96-well or 384-well microplates.

   • Allow the micro-structures to recover and establish basic organoid geometry for 3–4 days prior to introducing targeted small molecules, chemotherapeutic agents, or Antibody-Drug Conjugates (ADCs) across defined concentration gradients.

   • Maintain incubation for 72 to 120 hours. Quantify viability endpoints via the BioVector? CellTiter-Glo? 3D Cell Viability Assay (ATP-driven luminescent readout) to plot precise drug-dose response curves and determine absolute $IC_{50}$ metrics.

IV. Organoid Cryopreservation and Long-Term Archiving

• Cryoprotective Matrix Formulation: Specialized serum-free organoid freezing media are highly recommended. Alternatively, formulate: 80% complete organoid medium + 10% premium Fetal Bovine Serum (FBS) + 10% Dimethyl Sulfoxide (DMSO) + 10 $\mu\text{M}$ Y-27632.

• Rate-Controlled Freezing Schedule: During passaging, harvest cleanly dissociated multicellular clusters (avoid single-cell states) via centrifugation. Gently resuspend the organoid sediment in pre-chilled cryoprotective matrix and quickly aliquot into sterile cryogenic vials. Enclose the vials within a standardized container (such as a "Mr. Frosty" box) designed to drop the temperature at a predictable 1°C per minute inside a minus 80°C freezer overnight. Transfer the cryovials into the vapor phase of a liquid nitrogen storage tank (-196°C) the following day for indefinite preservation of structural architecture and physiological potency.

V. Quality Control Standards and Strategic Research Applications

• Quality Control Standards: Every batch of BioVector? PDO lines undergoes exhaustive clinical-grade quality validation. PCR screening certifies 100% negative status for Mycoplasma, bacteria, fungi, and prominent human blood-borne pathogens (including HIV, HBV, HCV). Short Tandem Repeat (STR) profiling confirms a 100% identity match with the original patient donor tissue. Whole Exome Sequencing (WES) and RNA-seq corroborate that the core oncogenic driver mutation configurations are faithfully preserved. The 3D architectural branching dynamics and multi-lineage differentiation profiles remain highly predictable across successive passage windows.

• Core Experimental Applications:

  • Companion Diagnostics & Personalized Oncology: Functioning as an individual patient "avatar" to screen therapeutic regimens in vitro before clinical administration, allowing clinicians to accurately anticipate patient-specific therapeutic responses.

  • Acquired Drug Resistance Dynamics: Utilizing advanced CRISPR-Cas9 plasmid systems to target and knock out specific genes directly within the PDO architecture, allowing researchers to map the molecular evolution of acquired resistance under prolonged exposure to EGFR or KRAS-G12C inhibitors.

  • Tumor Microenvironment (TME) Co-Culture Modeling: Establishing 3D co-cultures of PDOs alongside patient-autologous Tumor-Infiltrating Lymphocytes (TILs), Tumor-Associated Macrophages (TAMs), or Cancer-Associated Fibroblasts (CAFs). This setup provides an exceptional platform for tracking the spatial infiltration and functional cytotoxicity of novel CAR-T cell designs or bispecific antibodies within complex tissue barriers.

BioVector NTCC質(zhì)粒載體菌株細胞蛋白抗體基因保藏中心

電話:400-800-2947

工作QQ/微信同號:1843439339

網(wǎng)址

http://www.nedfriskphoto.com